Multicenter trial of the safety and efficacy of Certican [everolimus] in pediatric de novo renal transplant patients.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms RAD351
- Sponsors Novartis; Novartis Pharmaceuticals
- 29 Nov 2005 New trial record.